spacer
home > ebr > winter 2018 > back to the future
PUBLICATIONS
European Biopharmaceutical Review

Back to the Future

Globally, levels of antimicrobial resistance (AMR) are rising, and the shortage of effective medicines to treat microbial diseases such as pneumonia is severe. New approaches and innovations are urgently needed, but, for this to be realised, the way antibiotics are defined needs to change. Classes of medicines, such as vaccines and other immunotherapies, need to be brought into the fold. The challenge is that such new therapies will only progress to the clinic if stronger global efforts and financial support programmes encourage small enterprises to enter the market.

Using pneumococcal pneumonia as an example, this article explores the promising approaches that could prevent and cure this disease in vulnerable and developing populations and looks at the broader context of developing immunotherapeutic approaches to tackle growing levels of antimicrobial resistance.

Moving Beyond the Traditional


Given the increased threat of AMR, expanding the scope and classes of antimicrobial treatments beyond traditional smallmolecule drugs is important. Traditional antibiotics are facing increased resistance, and a spectrum of other treatments could play a significant role in combatting the rise of multi-drugresistant strains. Non-traditional classes of antibiotics include a wide range of combination therapies, phage therapy and immunotherapies such as antisera, antibodies and, particularly, vaccines given their preventive nature.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonas Elliott Gerson is co-founder and Director of Operations at PnuVax SL Biopharmaceuticals, Canada. He oversees product licensing, manufacturing and delivery of vaccines, including those for pneumonia and yellow fever. Jonas’s previous roles have included biopharmaceutical engineering and fuel cell research. He has an MASc in chemical engineering from Queen’s University, Canada.

Dr Donald Gerson is President and Chief Executive Officer of PnuVax SL Biopharmaceuticals, Canada, and has many years’ experience in vaccine and biopharma manufacturing management. He is former President and Chief Operating Officer of Celltrion and was previously Managing Director for manufacturing at Wyeth-Lederle Vaccines and Pediatrics. Donald has produced many vaccines to prevent and treat bacterial infections, as well as experimental vaccines for HIV and other diseases. Donald has also designed and constructed many biotech facilities around the world. He has a PhD in biophysics from McGill University, Canada.
spacer
Jonas Elliott Gerson
spacer
spacer
spacer
Dr Donald Gerson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Successfully managing the unique demands of cell therapy supply chains

PCI Pharma Services

Cell therapy professionals joined a specialist webinar by industry experts from PCI Clinical Services and TrakCel, addressing the unique complexity of an autologous therapy supply chain. Hosted by European Pharmaceutical Manufacturer magazine, the webinar was delivered by Rachel Griffiths, Associate Director, Technical Services, PCI Clinincal Services, and Dr. Matthew Lakelin, Vice President, Scientific Affairs and Business Development, TrakCel . Here, we present the white paper from that webinar event.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement